Skip to main content
Top
Published in: Inflammation 3/2015

01-06-2015

Natural Killer Cell Functional Activity After 4-1BB Costimulation

Authors: Shadi sadat Navabi, Mehrnoosh Doroudchi, Ahmad Hosseini Tashnizi, Mojtaba Habibagahi

Published in: Inflammation | Issue 3/2015

Login to get access

Abstract

Reports show enhancement of CD8 T cells’ activity through CD137 (4-1BB) signal; however, not all data proved similar effect in natural killer (NK) cells. Here, the impact of 4-1BB signal on NK cells’ function was assessed during short term cultures. To that end, cytokine-activated NK cells were cocultured with adenovirally transduced MCF-7 stimulator cells expressing 4-1BB ligand. Cellular cytotoxicity, cytokine production, and expression of cytotoxicity related genes were assessed after overnight cultures. Sharp decrease of CD56+ and CD56bright NK cells was demonstrated. 4-1BB neither enhanced cellular degranulation nor improved IFN-γ production although it promoted granzyme B, perforin, and FasL gene expression. 4-1BB signal stimulated higher proportions of CD56bright population to degranulate and express CD107a; however, it could not recover killing activity against K562 targets. Our data could not show major promotion in activity of all NK subpopulations. Due to great heterogeneity of NK cells, more investigation is needed to draw a comprehensive conclusion.
Literature
1.
go back to reference Inngjerdingen, M., L. Kveberg, C. Naper, and J.T. Vaage. 2011. Natural killer cell subsets in man and rodents. Tissue Antigens 78: 81–88.CrossRefPubMed Inngjerdingen, M., L. Kveberg, C. Naper, and J.T. Vaage. 2011. Natural killer cell subsets in man and rodents. Tissue Antigens 78: 81–88.CrossRefPubMed
2.
go back to reference Sun, J.C., S. Lopez-Verges, C.C. Kim, J.L. DeRisi, and L.L. Lanier. 2011. NK cells and immune “memory”. Journal of Immunology 186: 1891–1897.CrossRef Sun, J.C., S. Lopez-Verges, C.C. Kim, J.L. DeRisi, and L.L. Lanier. 2011. NK cells and immune “memory”. Journal of Immunology 186: 1891–1897.CrossRef
3.
go back to reference Bryceson, Y.T., M.E. March, H.G. Ljunggren, and E.O. Long. 2006. Activation, coactivation, and costimulation of resting human natural killer cells. Immunology Reviews 214: 73–91.CrossRef Bryceson, Y.T., M.E. March, H.G. Ljunggren, and E.O. Long. 2006. Activation, coactivation, and costimulation of resting human natural killer cells. Immunology Reviews 214: 73–91.CrossRef
4.
go back to reference Brigl, M., and M.B. Brenner. 2010. How invariant natural killer T cells respond to infection by recognizing microbial or endogenous lipid antigens. Seminars in Immunology 22: 79–86.CrossRefPubMed Brigl, M., and M.B. Brenner. 2010. How invariant natural killer T cells respond to infection by recognizing microbial or endogenous lipid antigens. Seminars in Immunology 22: 79–86.CrossRefPubMed
5.
go back to reference Long, E.O., H.S. Kim, D. Liu, M.E. Peterson, and S. Rajagopalan. 2013. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annual Review of Immunology 31: 227–258.CrossRefPubMed Long, E.O., H.S. Kim, D. Liu, M.E. Peterson, and S. Rajagopalan. 2013. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annual Review of Immunology 31: 227–258.CrossRefPubMed
7.
go back to reference Ortaldo, J.R., and H.A. Young. 2003. Expression of IFN-gamma upon triggering of activating Ly49D NK receptors in vitro and in vivo: costimulation with IL-12 or IL-18 overrides inhibitory receptors. Journal of Immunology 170: 1763–1769.CrossRef Ortaldo, J.R., and H.A. Young. 2003. Expression of IFN-gamma upon triggering of activating Ly49D NK receptors in vitro and in vivo: costimulation with IL-12 or IL-18 overrides inhibitory receptors. Journal of Immunology 170: 1763–1769.CrossRef
8.
go back to reference Watts, T.H. 2010. Staying alive: T cell costimulation, CD28, and Bcl-xL. Journal of Immunology 185: 3785–3787.CrossRef Watts, T.H. 2010. Staying alive: T cell costimulation, CD28, and Bcl-xL. Journal of Immunology 185: 3785–3787.CrossRef
9.
go back to reference Kinnear, G., N.D. Jones, and K.J. Wood. 2013. Costimulation blockade: current perspectives and implications for therapy. Transplantation 95: 527–535. Kinnear, G., N.D. Jones, and K.J. Wood. 2013. Costimulation blockade: current perspectives and implications for therapy. Transplantation 95: 527–535.
10.
go back to reference Scandiuzzi, L., K. Ghosh, and X. Zang. 2011. T cell costimulation and coinhibition: genetics and disease. Discovery Medicine 12: 119–128.PubMedCentralPubMed Scandiuzzi, L., K. Ghosh, and X. Zang. 2011. T cell costimulation and coinhibition: genetics and disease. Discovery Medicine 12: 119–128.PubMedCentralPubMed
11.
go back to reference Habib-Agahi, M., T.T. Phan, and P.F. Searle. 2007. Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells. International Immunology 19: 1383–1394.CrossRefPubMed Habib-Agahi, M., T.T. Phan, and P.F. Searle. 2007. Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells. International Immunology 19: 1383–1394.CrossRefPubMed
12.
13.
14.
go back to reference Baessler, T., J.E. Charton, B.J. Schmiedel, F. Grunebach, M. Krusch, A. Wacker, et al. 2010. CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells. Blood 115: 3058–3069.CrossRefPubMed Baessler, T., J.E. Charton, B.J. Schmiedel, F. Grunebach, M. Krusch, A. Wacker, et al. 2010. CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells. Blood 115: 3058–3069.CrossRefPubMed
15.
go back to reference Choi, B.K., Y.H. Kim, C.H. Kim, M.S. Kim, K.H. Kim, H.S. Oh, et al. 2010. Peripheral 4-1BB signaling negatively regulates NK cell development through IFN-gamma. Journal of Immunology 185: 1404–1411.CrossRef Choi, B.K., Y.H. Kim, C.H. Kim, M.S. Kim, K.H. Kim, H.S. Oh, et al. 2010. Peripheral 4-1BB signaling negatively regulates NK cell development through IFN-gamma. Journal of Immunology 185: 1404–1411.CrossRef
16.
go back to reference Buechele, C., T. Baessler, B.J. Schmiedel, C.E. Schumacher, L. Grosse-Hovest, K. Rittig, et al. 2012. 4-1BB ligand modulates direct and Rituximab-induced NK-cell reactivity in chronic lymphocytic leukemia. European Journal of Immunology 42: 737–748.CrossRefPubMed Buechele, C., T. Baessler, B.J. Schmiedel, C.E. Schumacher, L. Grosse-Hovest, K. Rittig, et al. 2012. 4-1BB ligand modulates direct and Rituximab-induced NK-cell reactivity in chronic lymphocytic leukemia. European Journal of Immunology 42: 737–748.CrossRefPubMed
17.
go back to reference Wang, X., D.A. Lee, Y. Wang, L. Wang, Y. Yao, Z. Lin, et al. 2013. Membrane-bound interleukin-21 and CD137 ligand induce functional human natural killer cells from peripheral blood mononuclear cells through STAT-3 activation. Clinical and Experimental Immunology 172: 104–112.CrossRefPubMedCentralPubMed Wang, X., D.A. Lee, Y. Wang, L. Wang, Y. Yao, Z. Lin, et al. 2013. Membrane-bound interleukin-21 and CD137 ligand induce functional human natural killer cells from peripheral blood mononuclear cells through STAT-3 activation. Clinical and Experimental Immunology 172: 104–112.CrossRefPubMedCentralPubMed
18.
go back to reference Melero, I., D. Hirschhorn-Cymerman, A. Morales-Kastresana, M.F. Sanmamed, and J.D. Wolchok. 2013. Agonist antibodies to TNFR molecules that costimulate T and NK cells. Clinical Cancer Research 19: 1044–1053.CrossRefPubMedCentralPubMed Melero, I., D. Hirschhorn-Cymerman, A. Morales-Kastresana, M.F. Sanmamed, and J.D. Wolchok. 2013. Agonist antibodies to TNFR molecules that costimulate T and NK cells. Clinical Cancer Research 19: 1044–1053.CrossRefPubMedCentralPubMed
19.
go back to reference Houot, R., H. Kohrt, and R. Levy. 2012. Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody. Oncoimmunology 1: 957–958.CrossRefPubMedCentralPubMed Houot, R., H. Kohrt, and R. Levy. 2012. Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody. Oncoimmunology 1: 957–958.CrossRefPubMedCentralPubMed
20.
go back to reference Wong, M.L., and J.F. Medrano. 2005. Real-time PCR for mRNA quantitation. Biotechniques 39: 75–85.CrossRefPubMed Wong, M.L., and J.F. Medrano. 2005. Real-time PCR for mRNA quantitation. Biotechniques 39: 75–85.CrossRefPubMed
21.
go back to reference Wortzman, M.E., D.L. Clouthier, A.J. McPherson, G.H. Lin, and T.H. Watts. 2013. The contextual role of TNFR family members in CD8(+) T-cell control of viral infections. Immunology Reviews 255: 125–148.CrossRef Wortzman, M.E., D.L. Clouthier, A.J. McPherson, G.H. Lin, and T.H. Watts. 2013. The contextual role of TNFR family members in CD8(+) T-cell control of viral infections. Immunology Reviews 255: 125–148.CrossRef
22.
go back to reference So, T., and M. Croft. 2013. Regulation of PI-3-kinase and Akt signaling in T lymphocytes and other cells by TNFR family molecules. Frontiers in Immunology 4: 139.CrossRefPubMedCentralPubMed So, T., and M. Croft. 2013. Regulation of PI-3-kinase and Akt signaling in T lymphocytes and other cells by TNFR family molecules. Frontiers in Immunology 4: 139.CrossRefPubMedCentralPubMed
23.
go back to reference Song, D.G., Q. Ye, C. Carpenito, M. Poussin, L.P. Wang, C. Ji, et al. 2011. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Research 71: 4617–4627.CrossRefPubMedCentralPubMed Song, D.G., Q. Ye, C. Carpenito, M. Poussin, L.P. Wang, C. Ji, et al. 2011. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Research 71: 4617–4627.CrossRefPubMedCentralPubMed
24.
go back to reference Dowell, A.C., K.A. Oldham, R.I. Bhatt, S.P. Lee, and P.F. Searle. 2012. Long-term proliferation of functional human NK cells, with conversion of CD56(dim) NK cells to a CD56 (bright) phenotype, induced by carcinoma cells co-expressing 4-1BBL and IL-12. Cancer Immunology, Immunotherapy 61: 615–628.CrossRefPubMed Dowell, A.C., K.A. Oldham, R.I. Bhatt, S.P. Lee, and P.F. Searle. 2012. Long-term proliferation of functional human NK cells, with conversion of CD56(dim) NK cells to a CD56 (bright) phenotype, induced by carcinoma cells co-expressing 4-1BBL and IL-12. Cancer Immunology, Immunotherapy 61: 615–628.CrossRefPubMed
25.
go back to reference St Rose, M.C., R.A. Taylor, S. Bandyopadhyay, H.Z. Qui, A.T. Hagymasi, A.T. Vella, et al. 2013. CD134/CD137 dual costimulation-elicited IFN-gamma maximizes effector T-cell function but limits Treg expansion. Immunology and Cell Biology 91: 173–183.CrossRefPubMed St Rose, M.C., R.A. Taylor, S. Bandyopadhyay, H.Z. Qui, A.T. Hagymasi, A.T. Vella, et al. 2013. CD134/CD137 dual costimulation-elicited IFN-gamma maximizes effector T-cell function but limits Treg expansion. Immunology and Cell Biology 91: 173–183.CrossRefPubMed
26.
go back to reference Fujisaki, H., H. Kakuda, N. Shimasaki, C. Imai, J. Ma, T. Lockey, et al. 2009. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Research 69: 4010–4017.CrossRefPubMedCentralPubMed Fujisaki, H., H. Kakuda, N. Shimasaki, C. Imai, J. Ma, T. Lockey, et al. 2009. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Research 69: 4010–4017.CrossRefPubMedCentralPubMed
28.
go back to reference Cho, D., D.R. Shook, N. Shimasaki, Y.H. Chang, H. Fujisaki, and D. Campana. 2010. Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clinical Cancer Research 16: 3901–3909.CrossRefPubMedCentralPubMed Cho, D., D.R. Shook, N. Shimasaki, Y.H. Chang, H. Fujisaki, and D. Campana. 2010. Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clinical Cancer Research 16: 3901–3909.CrossRefPubMedCentralPubMed
29.
go back to reference Milush, J.M., S. Lopez-Verges, V.A. York, S.G. Deeks, J.N. Martin, F.M. Hecht, et al. 2013. CD56negCD16(+) NK cells are activated mature NK cells with impaired effector function during HIV-1 infection. Retrovirology 10: 158.CrossRefPubMedCentralPubMed Milush, J.M., S. Lopez-Verges, V.A. York, S.G. Deeks, J.N. Martin, F.M. Hecht, et al. 2013. CD56negCD16(+) NK cells are activated mature NK cells with impaired effector function during HIV-1 infection. Retrovirology 10: 158.CrossRefPubMedCentralPubMed
30.
go back to reference Buechele, C., T. Baessler, S. Wirths, J.U. Schmohl, B.J. Schmiedel, and H.R. Salih. 2012. Glucocorticoid-induced TNFR-related protein (GITR) ligand modulates cytokine release and NK cell reactivity in chronic lymphocytic leukemia (CLL). Leukemia 26: 991–1000.CrossRefPubMed Buechele, C., T. Baessler, S. Wirths, J.U. Schmohl, B.J. Schmiedel, and H.R. Salih. 2012. Glucocorticoid-induced TNFR-related protein (GITR) ligand modulates cytokine release and NK cell reactivity in chronic lymphocytic leukemia (CLL). Leukemia 26: 991–1000.CrossRefPubMed
Metadata
Title
Natural Killer Cell Functional Activity After 4-1BB Costimulation
Authors
Shadi sadat Navabi
Mehrnoosh Doroudchi
Ahmad Hosseini Tashnizi
Mojtaba Habibagahi
Publication date
01-06-2015
Publisher
Springer US
Published in
Inflammation / Issue 3/2015
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-014-0082-0

Other articles of this Issue 3/2015

Inflammation 3/2015 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.